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The day hospital is the unit of care where, under a spe-
cialist physician’s supervision or indication, patients
undergoing complex diagnostic methods or treatment
requiring hours of continuous medical and/or nursing care,
but not hospital admission, are treated or receive care [1].
Day hospitals arose from the experience in hematology in
the USA in the 1970s. Patients with leukemias and lym-
phomas needed complex treatments, in addition to trans-
fusions, which entailed frequent care at the hospital.
Hospitalization, with the implications it had for these
patients’ quality of life and high associated costs, could be
avoided with these new care units. The rationale for the
monographic oncology day hospital (ODH) is that cancer
patient care accounts for 80% of the activity at general day
hospitals and calls for a well-defined diagnostic and ther-
apeutic care; furthermore, unlike other specialties, cancer
patients’ care demand is usually scheduled.
The ODH offers a broad spectrum of diagnostic and
therapeutic procedures (Table 1), making it possible to
improve the quality of life in patients with advanced dis-
ease—even combining the treatment of their illness while
remaining professionally active in some cases, relieving the
pressure of care on conventional hospital services and
decreasing health-care expenditure, a growing concern. As
a unit dedicated to medical treatment, the ODH will adapt
to the characteristics of patients receiving care and the
treatments they need. Consequently, it must have the
appropriate equipment and facilities, depending on the
service portfolio, and enable their activities to be scheduled
so as to optimize the care they provide. The role of
oncology nursing is key to achieving the aims of integral
patient care at the ODH, including patient intake, infor-
mation and education about treatments, and collaboration
in clinical research. Part of these activities must be con-
ducted in specific visits with the oncological nursing staff,
which already exist in most Spanish ODH. Suiting patient
needs will also entail changes in services as cancer diag-
nostics and treatments evolve.
The task force created for this purpose in 2015 by the
Sociedad Espan˜ola de Oncologı´a Me´dica (Spanish Society
for Medical Oncology) has assessed the current situation of
ODH in Spain by means of a questionnaire to which 52
oncology services of the 141 invited to participate
responded [2] and updated the previous survey
(2004–2005) [3]. The survey considered 62% of the ODH
to be monographic in comparison to 38% of the former
survey, with more architectural resources and equipment
(treatment chairs and beds available). The ODH is cur-
rently coordinated by a supervisor (54%) or the head of
department (40%) and has extensive personnel (median of
51.5 nurses, 7 nurse aides, and 2 administrative assistants);
more than 80% have an oncologist on duty in the after-
noon. In short, ODHs have developed considerably in the
last 10 years. Nevertheless, there is still room for
improvement in certain aspects: despite the remarkable
improvement in electronic global management systems at
Spanish hospitals compared to the previous survey, up to
15% of the ODHs do not have electronic oncological
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prescribing, reaching the 30% of ODH in larger hospitals
(in 2004–2005, 60% of the ODHs still had manual pre-
scription). Electronic appointment systems were in place in
77 and 46% had an electronic patient identification system,
although only 19% had a patient call display system in the
waiting room. One aspect in which much remains to be
done is in the area of quality control: only one-third of the
ODHs have some kind of system to monitor appointment
punctuality or delay in initiating treatments and only 30%
have an automatic, triple-data capture barcode scanner
(patient, nurse, and drug). Overall, 20% are quality stan-
dard certified, albeit this figure being even lower for
smaller hospitals (11%).
Clinical research is part of clinical oncology and ODH’s
daily activity. Of the patients cared for at the oncology
services, 10–15% are participating in a clinical trial. It is
therefore not surprising that, according to the survey, 67%
of ODH have research nursing staff and that 88% have
clinical research coordinators (commonly known as ‘‘data
managers’’).
As previously pointed out, one of the areas for
improvement of ODHs in Spain is computerization, par-
ticularly as regards prescribing chemotherapy. Electronic
prescription of the chemotherapy treatment order facilitates
the prescription process, integrating all the often complex
variables that come into play and finally contributes to
enhancing patient safety. In addition to decreasing medical
errors, it can also lower costs, shorten hospital stay, and
promote compliance with clinical guidelines [4]. Other
benefits include greater standardization of care, incorpo-
rating clinical decision processes into practice, better
interdepartmental communication, and possibility to obtain
data to quantify health-care practice for clinical research or
to evaluate the quality of the processes [5]. Moreover,
using an application for electronic chemotherapy pre-
scription can offer highly useful tools, such as notifications
of drug–drug interactions or allergies, warning about
inappropriate dosing, dose limitations based on age or
kidney function, or show reminders to administer other
support treatments, among others. The ENEAS 2005 study
highlights the importance of this facet by revealing that
37% of hospitalization-related adverse events in Spanish
hospitals have to do with medication, and, of these, 56%
can be considered avoidable [6]. The integration of phar-
macy departments into the ODH care team is a key issue to
achieving safe and efficient chemotherapy prescription. In
recent years, the gradual introduction of oral anti-neo-
plastic treatments with the same risks as with intravenous
administration has led to new needs surrounding safety and
reconciling medications and patient information, which we
believe make it mandatory to include these services also in
secure electronic prescription systems and make coordi-
nation with the oncological pharmacist and the ODH
nursing staff all the more necessary [7, 8].
Improving ODH care processes also means that activity
and quality indicators must be developed to enable the
evaluation and quantification of care activity. The SEOM
Day Hospital Task Force has proposed the incorporation of
a series of indicators related to care structure or activity, as
listed in Table 2 [2]. In addition, in light of the lack of
measurements of the quality of care, it proposes that a
catalog of quality indicators be created and agreed upon.
Once again, the use of computer systems that automatically
elaborate these indicators based on the quantification of
daily activity is fundamental to improve ODH manage-
ment. This is also a necessary step toward implementing
programs targeting patient safety and quality systems,
which will probably be the next step in developing ODHs
in our setting.
As regards the future, the ODH not only comprises the
critically important structure in outpatient cancer patient
care, but also forms the centerpiece where most innova-
tions in oncological treatment and the organization of
cancer patient care converge. The incorporation of new
technologies will enable this model to be expanded and
transformed, yielding new opportunities to communicate
with patients, monitor symptoms and treatment toxicity,
and coordinate with other structures and levels of care.
Telephone support for patients from the ODH, including
care for oncological emergencies and monitoring toxicity
[9], the use of e-mail in care processes, following existing
recommendations to guarantee its proper use [10], and the
Table 1 Day oncology hospital service portfolio
Administration of chemotherapy and targeted therapies
Medical consultation prior to treatment and assessment of
chemotherapy-induced and targeted therapy-induced toxicity
Consultation for patients participating in clinical trials
Blood and urine collection for laboratory analyses
Hemotherapy









Diagnostic or therapeutic paracentesis
Diagnostic or therapeutic thoracocentesis
Spinal tap
Direct line consultation with nursing staff
Reproduced with the authorization of the Spanish Society for Medical
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introduction of specific mobile applications to monitor
cancer patient’ symptoms or control toxicity [11–14], can
undoubtedly enhance patient care in the ODH. Finally,
important aspects to be developed in the ODH in the
coming years would be coordination with primary care
centers, their inclusion in the models of emergency care for
patients with cancer, and the possible integration of pal-
liative care within the structure of the ODH.
In conclusion, the members of the task force believe that
the ODH should be the center of multidisciplinary care for
cancer patients and that other models of care, more frag-
mented in the wake of the phasing out of the intravenous
route of administration, do not offer the necessary safety or
quality guarantees. The participation of clinical oncologists
in their management, in close collaboration with the other
professionals involved, is essential if the requirements as
regards integral, high-quality and efficient care are to be
met. In the coming years, we should witness the universal
implementation of computerized prescription and man-
agement systems, quality and safety program implemen-
tation in the ODH, the introduction of new patient
communication systems, and the organizational changes
required to address the challenge posed by new cancer
treatments. The introduction of accreditation programs,
preferably driven from the SEOM in collaboration with
other scientific societies, can be a key step toward
achieving these aims and to assure adequate care for cancer
patients.
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